Document:

Board of Directors of Avon Products, Inc. Deferred Compensation Plan

 Exhibit 10.22 
 BOARD OF DIRECTORS OF 
 AVON PRODUCTS, INC. 
 DEFERRED COMPENSATION PLAN  
 (As Amended and Restated Effective as of January 1, 2008) 

 BOARD OF DIRECTORS DEFERRED COMPENSATION PLAN 
  

			
	ELIGIBILITY	  	Any member of the Board of Directors of Avon Products, Inc. (the “Company”) who is not also an employee of the Company or its subsidiaries (a “Non-Employee Director”) may
participate in this Plan.
		
	DEFINITIONS	  	Capitalized words and phrases in this Plan and not otherwise defined herein shall have the same meaning as the definitions set forth in the Company’s 2005 Stock Incentive Plan to the
extent they are defined therein.
		
	ELECTION TO DEFER	  	 Each Non-Employee Director may elect to defer all or part of his or her cash compensation under Article II of the Company’s Compensation Plan
for Non-Employee Directors payable for the succeeding calendar year of service. This election must be in writing and must be made no later than December 31st of the year before the year in which the compensation to be deferred is earned. This
election will be made via election forms provided by the Company. To the extent that a Non-Employee Director makes this election prior to the applicable December 31st, then that election may be changed or revoked by the Non-Employee Director in
writing before or on the December 31st of the year before the year in which the compensation to be deferred is earned. Such change or revocation shall be made in accordance with procedures established by the Company from time to time. Thereafter,
any deferral election will be irrevocable. Any Non-Employee Director who elects to defer compensation in accordance with this Plan is hereinafter referred to as a “Participant.”
  
 As part of this election, a Participant must choose between crediting deferred amounts to the
“Deferred Cash Fund” or the “Deferred Stock Fund” (collectively, the “Account”). A Participant may choose to allocate deferred amounts within his or her Account in whole percentages.

		
	PAYMENT ELECTION	  	At the time a Participant makes his or her first deferral election under this Plan, a Participant must make a one-time election in writing as to whether he or she wishes to receive payment of
his or her Account in a single lump-sum or in annual installments, ranging from two to fifteen installments, pursuant to the “Payment of Account Balances” section below. This election will apply to all amounts deferred by a Participant
under this Plan. This election will be made via election forms provided by the Company. Notwithstanding the foregoing, certain Participants made this payment election prior to January 1, 2008 in accordance with transition rules issued under
Code Section 409A of the Internal Revenue Code. Those elections remain valid and are applicable to all amounts deferred by such Participants.

  

 1 

			
	BENEFICIARY DESIGNATION	  	Upon first becoming a Participant, and/or from time to time thereafter, a Participant may designate a beneficiary who shall be entitled to receive payment under this Plan in the event of the
Participant’s death. Beneficiary designations will be made in writing via forms provided by the Company. In the event that no beneficiary designation is made, or the Participant is not survived by a designated beneficiary, payment of any
Account balance under this Plan will be made to the Participant’s surviving spouse, if any, otherwise to the Participant’s estate.
		
	CREDITING OF DEFERRED AMOUNTS	  	The Company shall establish and maintain an individual Account in the name of each Participant. Compensation deferred during any calendar quarter will be credited to the applicable Account on
the last day of the calendar quarter in which the compensation otherwise would have been paid but for the election to defer.
		
	DEFERRED CASH FUND—QUARTERLY COMPOUNDING	  	All deferred compensation, including any accumulated interest, credited to a Participant’s Deferred Cash Fund as of the end of any calendar quarter will be credited with interest (on a
quarterly compounding basis) for such calendar quarter at a rate that shall be equal to the prime rate charged by JPMorgan Chase Bank, N.A. in effect on the last business day of the prior calendar year.
		
	DEFERRED STOCK FUND	  	 The total dollar amount credited to a Participant’s Deferred Stock Fund for any calendar quarter will be converted into a number of shares of
Stock equivalents, including fractions (“Stock Units”). The number of Stock Units so credited to such fund will be equal to the number of shares of Stock, including fractions, that could have been purchased with the amount of compensation
deferred for the calendar quarter at the closing price of a share of such Stock on the New York Stock Exchange averaged over the last ten trading days of the applicable calendar quarter.
  
 As of the date any dividend is paid to shareholders of Stock, the Participant’s Deferred Stock
Fund shall also be credited with additional Stock Units equal to the number of shares of Stock (including fractions of a share) that could have been purchased at the closing price of Stock on such date with the dividends paid on the number of shares
of Stock to which the Participant’s Stock Units are then equivalent.
  
 As of the end
of the calendar year in which the Participant, for any reason, ceases to be a member of the Board of Directors, the total number of his or her Stock Units, including fractions, will be converted to a cash value amount. In determining such amount,
each Stock Unit will be deemed to have a value equal to the closing price of a share of Stock on the New York Stock Exchange averaged over the last ten trading days of such calendar year. The resulting cash value will then be transferred into a
Deferred Cash Fund that is maintained for that Participant.
  
 If at any time the number
of the Company’s outstanding shares of Stock shall be adjusted in accordance with the terms of the Company’s 2005 Stock Incentive Plan, then the number of Stock Units to which such Stock is equivalent will be adjusted in the same
proportion.

  

 2 

			
	VALUATION OF ACCOUNTS	  	The cash value of a Participant’s Account, including any accumulated interest and Stock Units, will be determined each December 31st (a “Valuation Date”). For years in
which the Participant continues to be a member of the Board of Directors on the last day of such year, Stock Units will be valued for this purpose based on the closing price of a share of Stock on the New York Stock Exchange on the last trading day
of such year.
		
	PAYMENT OF ACCOUNT BALANCES	  	 The value of a Participant’s Account shall be payable in cash in a single payment in January of the year following the year in which such
Participant ceases to be a member of the Board of Directors. However, if otherwise previously elected by the Participant in accordance with this Plan, such value may be paid out in consecutive annual installments up to a maximum of fifteen annual
installments. All installment payments will be made in each January commencing with the year following the year in which such Participant ceases to be a member of the Board of Directors.
  
 Should a Participant elect installment payments, the amount of the first installment payment will be
a fraction of the value of such Participant’s Account on the preceding Valuation Date, the numerator of which is one and the denominator of which is the total number of annual installments elected. Thereafter, the amount of each subsequent
payment will be a fraction of the remaining value of such Participant’s Account on the Valuation Date preceding each subsequent installment payment, the numerator of which is one and the denominator of which is the total number of installments
elected minus the number of installments previously paid. Interest shall continue to accrue on the unpaid balance of the Account, credited annually in accordance with the “Deferred Cash Fund” section above.

		
	DEATH OF A DIRECTOR	  	Notwithstanding anything to the contrary in this Plan or any election by a Participant to receive installment payments, in the event of a Participant’s death any time prior to complete
distribution of all amounts payable under this Plan, the unpaid balance of such Participant’s Account, including any unpaid installments, will be determined as of the Valuation Date at the end of the calendar year in which the death occurs, and
will be paid in a single lump sum in the January immediately following such Valuation Date. All Stock Units credited to a Deferred Stock Fund will be converted to a cash value as described in the “Deferred Stock Fund” section above.
Payment will be made to the Participant’s beneficiary in accordance with this Plan.
		
	ADMINISTRATION	  	This Plan shall be administered by the Secretary of the Company, who shall have the power to interpret this Plan and delegate administrative duties under this Plan to others. The right to
receive compensation under this Plan may not be transferred, assigned, or subject to attachment or other legal process.

  

 3 

			
	AMENDMENT, SUSPENSION, AND TERMINATION	  	This Plan may be amended at any time by action of the Nominating and Corporate Governance Committee of the Board of Directors, provided that no amendment may adversely affect rights to
compensation deferred prior to the effective date of such amendment. This Plan may be suspended or terminated at any time by action of the Board of Directors, provided that all amounts deferred under this Plan will continue to be payable in
accordance with the terms of this Plan in effect at the time of such suspension or termination unless the Board of Directors provides otherwise.
		
	GOVERNING LAW	  	This Plan shall be governed by and subject to the laws of the State of New York and applicable Federal laws.

 The Company has caused this Plan to be amended and restated as of January 1, 2008.

  

			
	AVON PRODUCTS, INC.
		
	By:	 	 /s/ Kim K. Azzarelli

	Title:	 	VP, Associate General Counsel and Corporate Secretary
	Date:	 	December 5, 2007

  

 4Purchase Agreement, dated February 20, 2008

 Exhibit 10.1 
 THE NASDAQ STOCK MARKET, INC. 
 $425,000,000 
 2.50% Convertible Senior Notes due 2013 
 Purchase Agreement 
 February 20, 2008 
 J.P. Morgan Securities Inc.

 Banc of America Securities LLC 
 As Initial
Purchasers 
 c/o J.P. Morgan Securities Inc. 
 277 Park Avenue

 New York, New York 10172 
 Ladies and Gentlemen: 

The Nasdaq Stock Market, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities Inc. and Banc of
America Securities LLC (the “Initial Purchasers”), as listed in Schedule 1 hereto, $425,000,000 principal amount of its 2.50% Convertible Senior Notes due 2013 (the “Firm Securities”). The Firm Securities will be issued
pursuant to an Indenture (the “Indenture”), to be dated as of the Closing Date (as defined below), among the Company and The Bank of New York, as trustee (the “Trustee”). The Company also proposes to issue and sell to the Initial
Purchasers not more than an additional $50,000,000 principal amount of its 2.50% Convertible Senior Notes due 2013 (the “Additional Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the right
to purchase such Additional Securities granted to the Initial Purchasers in Section 1 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred to as the “Securities.” The Securities will be
convertible into cash, shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”), or a combination thereof. 
 The Securities will be sold to the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the “Securities
Act”), in reliance upon an exemption therefrom. The Company has prepared a preliminary offering memorandum dated February 20, 2008 (including the documents incorporated by reference therein, the “Preliminary Offering Memorandum”)
and will prepare an offering memorandum dated the date hereof (including the documents incorporated by reference therein, the “Offering Memorandum”) setting forth information concerning the Company and the Securities. Copies of the
Preliminary Offering Memorandum have been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this Agreement. The Company hereby confirms that it has authorized the use of the
Preliminary Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection with the offering and resale of the Securities by the Initial Purchasers in the manner contemplated by this Agreement.

 At or prior to the time when sales of the Securities were first made (the “Time of Sale”), the
following information shall have been prepared (collectively, the “Time of Sale Information”): the Preliminary Offering Memorandum, as supplemented and amended by the written communications listed on Annex A hereto. 
 Holders of the Securities (including the Initial Purchasers and their direct and indirect transferees) will be entitled to the benefits of a Registration
Rights Agreement, to be dated the Closing Date (as defined below) and substantially in the form attached hereto as Exhibit A (the “Registration Rights Agreement”), pursuant to which the Company will agree to file one or more registration
statements with the Securities and Exchange Commission (the “Commission”) under certain circumstances, which registration statements would provide for the registration under the Securities Act of the Securities. 
 The Securities are being issued and sold as part of the financing necessary to effect (a) the Transactions (as defined below), including the
acquisition of not less than 67 percent of the outstanding capital stock of OMX AB (publ), a company incorporated and organized under the laws of Sweden, with corporate registration number 556243-8001 (“OMX”), held by Borse Dubai Limited,
a company registered in the Dubai International Financial Centre in Dubai with company number CL0447 (“Borse Dubai”), and BD Stockholm AB, a corporation organized under the laws of Sweden (“Bidder”), pursuant to the transaction
agreement, dated as of November 15, 2007, by and among the Company, Borse Dubai and Bidder (the “OMX Transaction Agreement”), (b) the refinancing of certain indebtedness of OMX and (c) the payment of all fees, costs and
expenses incurred or payable by the Company or any of its subsidiaries in connection with the Transactions. For the purposes of this Agreement, the term “Transactions” has the meaning given such term in the Preliminary Offering Memorandum.
The Transactions and any related premiums, fees and expenses will be financed from the following sources: (1) the issuance of Common Stock to Borse Dubai described in the Time of Sale Information and the Offering Memorandum (the “Equity
Investment”); (2) loans under a senior secured credit facility as described in the Time of Sale Information and the Offering Memorandum (together with any other documents, agreements or instruments delivered in connection therewith, the
“Credit Facility”), which shall also be used to finance the continuing operations of the Company and its subsidiaries after the Transactions, (3) cash on hand and (4) cash proceeds from the issuance of the Securities. 

The Company hereby confirms its agreement with the several Initial Purchasers concerning the purchase and resale of the Securities, as follows:

 1. Purchase and Resale of the Securities. 
 (a) The Company agrees to issue and sell the Securities to the several Initial Purchasers as provided in this Agreement, and each Initial Purchaser, on the basis of the representations, warranties and agreements set
forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company the respective principal amount of Securities set forth opposite such Initial Purchaser’s name in Schedule 1 hereto at
a price equal to 98.125% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any, from February 26, 2008 to the Closing Date. 
 On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Initial Purchasers the Additional Securities, and the Initial
Purchasers shall have the right to purchase, in the same proportion as the Securities are purchased as set forth in Schedule 1, in whole, or from time to time in part, up to $50,000,000 principal amount of Additional Securities, solely to cover
over-allotments, at the Purchase Price plus accrued interest, if any, from the Closing Date (as defined below) to the date of payment and delivery. 

 If you, on behalf of the Initial Purchasers, exercise such option, you shall so notify the Company in
writing, which notice shall specify the principal amount of Additional Securities to be purchased by the Initial Purchasers and the date on which such Additional Securities are to be purchased. Such date must be within a 30-day period from, and
including, the Closing Date. 
 The Company will not be obligated to deliver any of the Securities except upon payment for all the Securities
to be purchased as provided herein. 
 (b) The Company understands that the Initial Purchasers intend to offer the Securities for resale on
the terms set forth in the Time of Sale Information. Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 
 (i) it is a qualified institutional buyer within the meaning of Rule 144A under the Securities Act (a “QIB”) and an accredited investor within the meaning of Rule 501(a) under the Securities Act; 

(ii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities by means of
any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D under the Securities Act (“Regulation D”) or in any manner involving a public offering within the meaning of Section 4(2) of the
Securities Act; and 
 (iii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or
sell, the Securities as part of their initial offering except within the United States to persons whom it reasonably believes to be QIBs in transactions pursuant to Rule 144A under the Securities Act (“Rule 144A”) and in connection with
each such sale, it has taken or will take reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on Rule 144A. 
 (c) Each Initial Purchaser acknowledges and agrees that the Company and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant to Section 6(f), counsel for the Company may rely upon the
accuracy of the representations and warranties of the Initial Purchasers, and compliance by the Initial Purchasers with their agreements, contained in paragraph (b) above, and each Initial Purchaser hereby consents to such reliance. 

(d) The Company acknowledges and agrees that the Initial Purchasers may offer and sell Securities to or through any affiliate of an Initial Purchaser
and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser. 
 (e) The Company
acknowledges and agrees that the Initial Purchasers are acting solely in the capacity of an arm’s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with
determining the terms of the offering) and not as financial advisors or fiduciaries to, or agents of, the Company or any other person. Additionally, no Initial Purchaser is advising the Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated
hereby, and the Initial Purchasers shall not, either jointly or severally, have any responsibility or liability to the Company with respect thereto. Any review by any Initial Purchaser of the Company, and the transactions contemplated hereby or
other matters relating to such transactions will be performed solely for the benefit of such Initial Purchaser, and shall not be on behalf of the Company or any other person. 

 2. Payment and Delivery. 
 (a) Payment for and delivery of the Firm Securities will be made at the offices of Skadden, Arps, Slate, Meagher & Flom LLP at 10:00 A.M., New
York City time, on February 26, 2008, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Initial Purchasers and the Company may agree upon in writing. The time and date of
such payment and delivery is referred to herein as the “Closing Date.” 
 Payment for and delivery of the Additional Securities
will be made at the offices of Skadden, Arps, Slate, Meagher & Flom LLP at 10:00 A.M., New York City time, on the date specified in the notice described in Section 1 or at such other time or place on the same or such other date, not
later than February 29, 2008, as the Initial Purchasers and the Company may agree upon in writing. The time and date of such payment and delivery is referred to herein as the “Optional Closing Date.” 
 (b) Payment for the Firm Securities and Additional Securities shall be made by wire transfer in immediately available funds to the account(s) specified
by the Company to the Initial Purchasers against delivery to the nominee of The Depository Trust Company (“DTC”), for the account of the Initial Purchasers, of one or more global notes representing the Firm Securities and Additional
Securities (collectively, the “Global Note”), with any transfer taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Note will be made available for inspection by the Initial Purchasers not later
than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Optional Closing Date, as the case may be. 
 3.
Representations and Warranties of the Company. The Company represents and warrants to each Initial Purchaser that: 
 (a) Preliminary Offering Memorandum, Time of Sale Information and Offering Memorandum. The Preliminary Offering Memorandum, as of its date, did not, the Time of Sale Information, at the Time of Sale, did not, and at the Closing Date,
will not, and the Offering Memorandum, in the form first used by the Initial Purchasers to confirm sales of the Securities and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in
reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser expressly for use in the Preliminary Offering Memorandum, the Time of Sale Information or the Offering
Memorandum. 
 (b) Additional Written Communications. The Company (including its agents and representatives, other than
the Initial Purchasers in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any written communication that constitutes an offer to sell or
solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives (other than a communication referred to in clauses (i), (ii) and (iii) below) an “Issuer Written
Communication”) other than (i) the Preliminary Offering Memorandum, (ii) the Offering Memorandum, (iii) the documents listed on Annex A hereto, including a term sheet substantially in the form of Annex B hereto, which constitute
part of the Time of Sale Information, and (iv) any electronic road 

 
show or other written communications, in each case used in accordance with Section 4(c). Each such Issuer Written Communication, when taken together
with the Time of Sale Information, did not, and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance upon and in conformity with
information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser expressly for use in any Issuer Written Communication. 
 (c) Financial Statements. The financial statements and the related notes thereto included in each of the Time of Sale Information
and the Offering Memorandum present fairly the financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial
statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods covered thereby; the other financial information included in each of the Time of Sale Information and the
Offering Memorandum has been derived from the accounting records of the Company and its subsidiaries and presents fairly the information shown thereby; and the pro forma financial information and the related notes thereto included in
each of the Time of Sale Information and the Offering Memorandum has been prepared in accordance with the Commission’s rules and guidance with respect to pro forma financial information, and the assumptions underlying such
pro forma financial information are reasonable and are set forth in each of the Time of Sale Information and the Offering Memorandum. 
 (d) No Material Adverse Change. Since the date of the most recent financial statements of the Company included in each of the Time of Sale Information and the Offering Memorandum, except as otherwise set forth
or contemplated in the Time of Sale Information and the Offering Memorandum, (i) there has not been any change in the capital stock, increase in long-term debt or any decreases in consolidated net current assets or stockholders’ equity of
the Company and its subsidiaries taken as a whole, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a
prospective material adverse change, in or affecting the business, properties, management, financial position, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its
subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries
taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Time of Sale Information. 

 (e) Organization and Good Standing. The Company and each of its subsidiaries have
been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership
or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except
where the failure to be so qualified, in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, results of operations or
prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under the Securities (a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any
corporation, association or other entity other than the subsidiaries listed in Schedule 2 to this Agreement under “The Company and its subsidiaries”. 
 (f) Capitalization. The Company has an authorized capitalization as set forth in each of the Time of Sale Information and the
Offering Memorandum under the heading “Capitalization”; such authorized capital stock of the Company conforms as to legal matters in all material respects to the description thereof contained in the Time of Sale Information and the
Offering Memorandum; there are no outstanding options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or any contracts or commitments to issue or sell, any shares of Common Stock, any
shares of capital stock of any subsidiary, or any such warrants, convertible securities or obligations, except as set forth in the Time of Sale Information and the Offering Memorandum and except for options granted under, or contracts or commitments
pursuant to, the Company’s previous or currently existing stock option and other similar officer, director or employee benefit plans; except for this Agreement, the Registration Rights Agreement, the registration rights agreement which governs
the registration of the Company’s Common Stock acquired by Borse Dubai and the Trust (the “Dubai Registration Rights Agreement”), the registration rights agreement dated April 21, 2005 between the Company and investors defined
therein (the “SLP Registration Rights Agreement”) or stock purchase plans, there are no contracts, commitments, agreements, arrangements, understandings or undertakings of any kind to which the Company is a party, or by which it is bound,
granting to any person the right to require either the Company to file a registration statement under the Securities Act with respect to any securities of the Company or requiring the Company to include such securities with the Securities registered
pursuant to any registration statement; the shares of Common Stock outstanding on the date hereof have been duly authorized and are validly issued, fully paid and non-assessable; and all the outstanding shares of capital stock or other equity
interests of each of the Company’s subsidiaries have been duly and validly authorized and issued, are fully paid and non-assessable (except in the case of any foreign subsidiary) and are owned directly or indirectly by the Company or OMX, as
applicable, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party, other than to the extent required by the Credit Facility. 

 (g) Due Authorization. The Company has full right, power and authority to execute
and deliver this Agreement, the Securities, the Indenture, the Registration Rights Agreement, the OMX Transaction Agreement, and the Credit Facility (collectively, the “Transaction Documents”) to which each is a party and to perform their
respective obligations hereunder and thereunder; and all action required to be taken for the due and proper authorization, execution and delivery of each of the Transaction Documents and the consummation of the transactions contemplated thereby has
been duly and validly taken. 
 (h) The Indenture. The Indenture has been duly authorized by the Company and, when duly
executed and delivered in accordance with its terms, will constitute a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency or similar laws affecting the enforcement of creditors’ rights generally or by equitable principles relating to enforceability (collectively, the “Enforceability Exceptions”); and on the Closing Date, the Indenture will
conform in all material respects to the requirements of the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the rules and regulations of the Commission applicable to an indenture that is qualified thereunder.

 (i) The Securities. The Securities have been duly authorized by the Company and, when duly executed, authenticated,
issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance
with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 
 (j)
The Underlying Securities. Upon issuance and delivery of the Securities in accordance with the Agreement and the Indenture, the Securities will be convertible at the option of the holder thereof into cash, shares of the Underlying Securities,
or a combination thereof in accordance with the terms of the Securities; the Underlying Securities reserved for issuance upon conversion of the Securities have been duly authorized and reserved and, when and if issued upon conversion of the
Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of any Underlying Securities will not be subject to any preemptive or similar rights. 
 (k) Purchase and Registration Rights Agreements. This Agreement has been duly authorized, executed and delivered by the Company;
and the Registration Rights Agreement has been duly authorized by the Company and on the Closing Date will be duly executed and delivered by the Company and, when duly executed and delivered in accordance with its terms by each of the parties
thereto, will constitute a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions, and except that rights to indemnity and contribution thereunder may
be limited by applicable law and public policy. 

 (l) Other Transaction Documents. Each of the OMX Transaction Agreement and the
Credit Facility has been duly authorized by the Company and, when duly executed and delivered in accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company enforceable against the
Company in accordance with its terms, subject to the Enforceability Exceptions. 
 (m) Descriptions of the Transaction
Documents. Each Transaction Document conforms in all material respects to the description thereof contained in each of the Time of Sale Information and the Offering Memorandum. 
 (n) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or
similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of
the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses
(ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. 
 (o) No Conflicts. The execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party, the issuance and sale of the Securities (including the issuance of any
Underlying Securities upon conversion thereof) and compliance by the Company with the terms thereof and the consummation of the transactions contemplated by the Transaction Documents will not (i) conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would not,
individually or in the aggregate, have a Material Adverse Effect. 
 (p) No Consents Required. No consent, approval,
authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of each of the Transaction Documents, the issuance
and sale of the Securities (including the issuance of any Underlying Securities upon conversion thereof ) and compliance by the Company with the terms thereof and the consummation of the 

 
transactions contemplated by the Transaction Documents, except for such consents, approvals, authorizations, orders and registrations or qualifications as
may be required under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers. 
 (q) Legal Proceedings. Except as described in each of the Time of Sale Information and the Offering Memorandum, there are no legal, governmental or regulatory investigations, actions, suits or proceedings
pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company
or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; and no such investigations, actions, suits or proceedings are threatened or, to the best knowledge of the Company, contemplated by any governmental or
regulatory authority or by others. 
 (r) Independent Accountants. (i) Each of Ernst & Young LLP, who has
certified certain financial statements of the Company and its subsidiaries (other than OMX and its subsidiaries), and Grant Thornton LLP, who has certified certain financial statements of PHLX and its subsidiaries, are independent public accountants
with respect to the Company and PHLX and their respective subsidiaries, as applicable, within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) or, in the case of PHLX,
within the meaning of Rule 101 of the Code of Professional Conduct of the American Institute of Certified Public Accountants and its interpretations and rulings thereunder, and as required by the Securities Act and (ii) PricewaterhouseCoopers
AB, who has certified certain financial statements of OMX and its subsidiaries, is an independent public accountant with respect to OMX and its subsidiaries with the applicable Swedish rules and regulations. 
 (s) Title to Intellectual Property. The Company and its subsidiaries own or possess adequate rights to use all material patents,
patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) necessary for the conduct of their respective businesses; and the conduct of their respective businesses will not conflict in any material respect with any such rights of others, and the Company and its
subsidiaries have not received any notice of any claim of infringement of or conflict with any such rights of others which infringement or conflict (if the subject of any unfavorable decision, ruling or finding), would reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect. 
 (t) No Undisclosed Relationships. No
relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders or other affiliates of the Company or any of its subsidiaries, on the other, that would be
required by the Securities Act to be described in a registration statement to be filed with the Commission and that is not so described in each of the Time of Sale Information and the Offering Memorandum. 

 (u) Investment Company Act. Neither the Company nor any of its subsidiaries is,
and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in each of the Time of Sale Information and the Offering Memorandum none of them will be, an “investment company”
or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder. 
 (v) Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns
required to be paid or filed through the date hereof, except insofar as any failures to file such returns or pay such taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and there are no tax
deficiencies that have been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets, except to the extent of any tax deficiency that would not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (w) Licenses and Permits. The Company
and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are
necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Time of Sale Information and the Offering Memorandum, except where the failure to possess or make the same
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Time of Sale Information and the Offering Memorandum, and except as would not reasonably be expected to
have a Material Adverse Effect, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license,
certificate, permit or authorization will not be renewed in the ordinary course. 
 (x) Compliance With ERISA.
(i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as
any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the “Code”)), which shall not include OMX or its subsidiaries, would have any
liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited
transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that
is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code, whether or not waived, has occurred or is reasonably expected to
occur; (iv) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v) no 

 
“reportable event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur; and (vi) neither the
Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect
of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of ERISA). 
 (y)
Disclosure Controls. The Company and its subsidiaries, with the exception of OMX and its subsidiaries, maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is
designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules
and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its
subsidiaries, with the exception of OMX and its subsidiaries, have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. OMX and its subsidiaries have carried out
evaluations of the effectiveness of their disclosure controls as required by Swedish Companies Act, Exchange and Clearing Act, Act on trading with certain financial instruments, Act on Annual Reporting, Act on notification of certain holdings of
financial instruments and listing contracts with the Nordic Exchange in Stockholm, Helsinki, Copenhagen and Reykavik. 
 (z)
Accounting Controls. The Company and its subsidiaries, with the exception of OMX, PHLX and their subsidiaries, maintain systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that
comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company and these subsidiaries maintain internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in each of the Time of Sale Information and the Offering Memorandum,
there are no material weaknesses or significant deficiencies in the Company’s internal controls. OMX, PHLX and their subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including, but not limited to internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance 

 
with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 
 (aa) Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in
amounts and insures against such losses and risks as are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent
of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance except as would not reasonably be expected to have a Material Adverse Effect or (ii) any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. 
 (bb) Stock Options. With respect to the stock options (the “Stock Options”) granted pursuant to the stock-based
compensation plans of the Company and its subsidiaries except for OMX and its subsidiaries (the “Company Stock Plans”), (i) each Stock Option designated by the Company or the relevant subsidiary of the Company at the time of grant as
an “incentive stock option” under Section 422 of the Code so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the
“Grant Date”) by all necessary corporate action, (iii) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including
the rules of The Nasdaq Global Select Market and any other exchange on which the securities of the Company or the relevant subsidiary of the Company are traded, (iv) the per share exercise price of each Stock Option was equal to or greater than
the fair market value of a share of Common Stock on the applicable Grant Date and (v) each such grant was properly accounted for in accordance with generally accepted accounting principles in the consolidated financial statements (including the
related notes) of the Company and disclosed in the Company’s filings with the Commission in accordance with the Exchange Act and all other applicable laws. Neither the Company nor any of its subsidiaries has knowingly granted, and there is no
and has been no policy or practice of the Company or any of its subsidiaries of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding
the Company or its subsidiaries or their results of operations or prospects. 
 (cc) No Unlawful Payments. Neither the
Company nor any of its subsidiaries nor, to the best knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company and any of its subsidiaries has (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct 

 
or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) except for OMX and its subsidiaries,
violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977; or (iv) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment. Neither OMX, nor its subsidiaries, nor any director,
officer, agent, employee or other person associated with or acting on behalf of OMX and any of its subsidiaries has violated or is in violation of any provision of applicable foreign anti-bribery laws.
 (dd) Compliance with Money Laundering Laws. The operations of the Company and its subsidiaries, except for OMX and its
subsidiaries, are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all
jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
The operations of OMX and its subsidiaries are and have been conducted in compliance with the applicable financial recordkeeping and reporting statutes and requirements and applicable money laundering statutes, and rules and regulations
thereunder, and no investigation, action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving OMX or any of its subsidiaries with respect to the applicable financial
recordkeeping and reporting statutes and requirements and applicable money laundering statutes is pending or threatened.
 (ee) Compliance with OFAC. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries, except for OMX and its
subsidiaries, is currently in violation of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”); and the Company will not directly or indirectly use the proceeds of the
offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person or activities currently
in violation of any U.S. sanctions administered by OFAC. Neither OMX, nor its subsidiaries, nor any director, officer, agent or employee or affiliate of OMX and its subsidiaries is in violation of applicable sanctions programs. 

(ff) No Restrictions on Subsidiaries. Except as required by the Credit Facility, no subsidiary of the Company is currently
prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock, from repaying to
the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company; provided that the foregoing representation shall not
be deemed to apply to OMX and its subsidiaries and any 

 
subsidiary of the Company that is a “Foreign Subsidiary” or an “Excluded Subsidiary”, each as defined in the draft credit agreement
posted on IntraLinks as of the date of this Agreement. 
 (gg) No Broker’s Fees. Neither the Company nor any of
its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Initial Purchaser for a brokerage commission, finder’s fee or
like payment in connection with the offering and sale of the Securities. 
 (hh) Rule 144A Eligibility. On the Closing
Date, the Securities will not be of the same class as securities listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in an automated inter-dealer quotation system; and each of the Preliminary
Offering Memorandum and the Offering Memorandum, as of its respective date, contains or will contain all the information that, if requested by a prospective purchaser of the Securities, would be required to be provided to such prospective purchaser
pursuant to Rule 144A(d)(4) under the Securities Act. 
 (ii) No Integration. Neither the Company nor any of its
affiliates (as defined in Rule 501(b) of Regulation D) has, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be
integrated with the sale of the Securities in a manner that would require registration of the Securities under the Securities Act. 
 (jj) No General Solicitation or Directed Selling Efforts. None of the Company or any of its affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as to which no representation is made) has
solicited offers for, or offered or sold, the Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of
Section 4(2) of the Securities Act. 
 (kk) Securities Law Exemptions. Assuming the accuracy of the
representations and warranties of the Initial Purchasers contained in Section 1(b) their compliance with their agreements set forth therein, it is not necessary, in connection with the issuance and sale of the Securities to the Initial
Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, to register the Securities under the Securities Act or
to qualify the Indenture under the Trust Indenture Act. 
 (ll) No Stabilization. The Company has not taken, directly
or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. 
 (mm) Margin Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the
Company as described in each of the Time of Sale Information and the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. 

 (nn) Forward-Looking Statements. No forward-looking statement (within the meaning
of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in any of the Time of Sale Information or the Offering Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than
in good faith. 
 (oo) Statistical and Market Data. Nothing has come to the attention of the Company that has caused
the Company to believe that the statistical and market-related data included in each of the Time of Sale Information and the Offering Memorandum is not based on or derived from sources that are reliable and accurate in all material respects.

 (pp) Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s
directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and
906 related to certifications. 
 4. Further Agreements of the Company. The Company covenants and agrees with each Initial Purchaser
that: 
 (a) Delivery of Copies. The Company will deliver, without charge, to the Initial Purchasers as many copies of the Preliminary
Offering Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments and supplements thereto) as the Initial Purchasers may reasonably request. 
 (b) Offering Memorandum, Amendments or Supplements. Before finalizing the Offering Memorandum or making or distributing any amendment or
supplement to any of the Time of Sale Information or the Offering Memorandum, the Company will furnish to the Initial Purchasers and counsel to the Initial Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement for
review, and will not distribute any such proposed Offering Memorandum, amendment or supplement or file any such document with the Commission to which the Initial Purchasers reasonably object promptly. 
 (c) Additional Written Communications. Before making, preparing, using, authorizing, approving or referring to any Issuer Written Communication,
the Company will furnish to the Initial Purchasers and counsel to the Initial Purchasers a copy of such written communication for review and will not make, prepare, use, authorize, approve or refer to any such written communication to which the
Initial Purchasers reasonably object promptly. 
 (d) Notice to the Initial Purchasers. The Company will advise the Initial Purchasers
promptly, and confirm such advice in writing, (i) of the issuance by any governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering
Memorandum or the initiation or threatening of any proceeding for that purpose; (ii) of the occurrence of any event at any time 

 
prior to the completion of the initial offering of the Securities as a result of which any of the Time of Sale Information, any Issuer Written Communication
or the Offering Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when such
Time of Sale Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser, not misleading; and (iii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the
Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order preventing or suspending the use of
any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.

 (e) Time of Sale Information. If at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a
result of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading or (ii) it is necessary to amend or supplement any of the Time of Sale Information to comply with law, the Company will immediately notify the Initial Purchasers thereof and forthwith
prepare and, subject to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to any of the Time of Sale Information as may be necessary so that the statements in any of the Time of Sale Information as so amended
or supplemented will not, in light of the circumstances under which they were made, be misleading or so that any of the Time of Sale Information will comply with law. 
 (f) Ongoing Compliance of the Offering Memorandum. If at any time prior to the completion of the initial offering of the Securities (i) any event shall occur or condition shall exist as a result of which
the Offering Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the
Offering Memorandum is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Offering Memorandum to comply with law, the Company will immediately notify the Initial Purchasers thereof and forthwith prepare
and, subject to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to the Offering Memorandum as may be necessary so that the statements in the Offering Memorandum as so amended or supplemented will not, in
the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, be misleading or so that the Offering Memorandum will comply with law. 
 (g) Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Initial Purchasers shall reasonably request and will
continue such qualifications in effect so long as required for the offering and resale of the Securities; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in
securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is
not otherwise so subject. 

 (h) Clear Market. Without the prior written consent of the Initial Purchasers, the Company will
not, during the period ending 60 days after the date of the Offering Memorandum, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (other than issuances of shares of Common Stock in connection
with the Company’s secondary listing of shares on the OMX Nordic Exchange and DIFX), (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common
Stock, (iii) file with the Commission a registration statement under the Securities Act relating to any additional shares of its Common Stock or securities convertible into, or exchangeable for, any shares of its Common Stock (other than a
registration statement on Form S-8, with respect to any of the foregoing and other than in connection with the SLP Registration Rights Agreement or the Dubai Registration Rights Agreement) or publicly disclose the intention to effect any transaction
described in clause (i), (ii) or (iii), whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; provided that the foregoing
shall not apply to (A) the sale of the Securities under this Agreement or the issuance of any Underlying Securities, (B) the issuance of shares of Common Stock pursuant to existing employee benefit plans of the Company, the grant by the
Company of employee or director stock options in the ordinary course of business, the issuance by the Company of any shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof,
(C) the issuance of any shares of Common Stock in connection with the Transactions as described in the Offering Memorandum, (D) the issuance of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock
in connection with (i) the acquisition of all or substantially all or significantly all of the assets, property or equity of another person or all or substantially all or significantly all of the assets, property or equity of a subsidiary,
business segment, business unit or business division thereof or (ii) the merger or consolidation or similar transaction of the Company or any wholly owned subsidiary of the Company with another person, (E) the filing of any registration
statement in respect of the Securities and the Underlying Securities; provided, further, that the Company will notify the Initial Purchasers upon any issuance pursuant to clause (E) above. Notwithstanding the foregoing, if
(1) during the last 17 days of the 60-day restricted period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or (2) prior to the expiration of the 60-day restricted period, the
Company announces that it will release earnings results during the 16-day period beginning on the last day of the 60-day period, the restrictions imposed by this Agreement shall continue to apply until the expiration of the 18-day period beginning
on the issuance of the earnings release or the occurrence of the material news or material event. 
 (i) Use of Proceeds. The Company
will apply the net proceeds from the sale of the Securities as described in each of the Time of Sale Information and the Offering Memorandum under the heading “Use of proceeds.” 

 (j) Underlying Securities. The Company will reserve and keep available at all times, free of
pre-emptive rights, shares of Common Stock for the purpose of enabling the Company to satisfy all obligations to issue any Underlying Securities upon conversion of the Securities. The Company will use its best efforts to cause the Underlying
Securities to be listed on The Nasdaq Global Select Market (the “Exchange”). 
 (k) Supplying Information. While the
Securities remain outstanding and are “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act, the Company will, during any period in which the Company is not subject to and in compliance with Section 13
or 15(d) of the Exchange Act, furnish to holders of the Securities and prospective purchasers of the Securities designated by such holders, in each case upon request, the information required to be delivered pursuant to Rule 144A(d)(4) under the
Securities Act. 
 (l) PORTAL and DTC. The Company will assist the Initial Purchasers in arranging for the Securities to be designated
Private Offerings, Resales and Trading through Automated Linkages (“PORTAL”) Market securities in accordance with the rules and regulations adopted by the Financial Industry Regulatory Authority (“FINRA”) relating to trading in
the PORTAL Market and for the Securities to be eligible for clearance and settlement through DTC. 
 (m) Indenture Qualification.
Prior to any registration of the Securities pursuant to the Registration Rights Agreement, or at such earlier time as may be so required, the Company will qualify the Indenture under the Trust Indenture Act and enter into any necessary supplemental
indentures in connection therewith. 
 (n) No Resales by the Company. During the period from the Closing Date until one year after the
Closing Date, or the Option Closing Date, if applicable, the Company will not, and will not permit any of its affiliates (as defined in Rule 144 under the Securities Act) to, resell any of the Securities that have been acquired by any of them,
except for Securities purchased by the Company or any of its affiliates and resold in a transaction registered under the Securities Act. 
 (o) No Integration. Neither the Company nor any of its affiliates (as defined in Rule 501(b) of Regulation D) will, directly or through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any
security (as defined in the Securities Act), that is or will be integrated with the sale of the Securities in a manner that would require registration of the Securities under the Securities Act. 
 (p) No General Solicitation or Directed Selling Efforts. None of the Company or any of its affiliates or any other person acting on its or their
behalf (other than the Initial Purchasers, as to which no covenant is given) will (i) solicit offers for, or offer or sell, the Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of
Regulation D or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act or (ii) engage in any directed selling efforts within the meaning of Regulation S, and all such persons will comply with the
offering restrictions requirement of Regulation S. 
 (q) No Stabilization. The Company will not take, directly or indirectly, any
action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities and will not take any action prohibited by Regulation M under the Exchange Act in connection with the
distribution of the Securities contemplated hereby. 

 5. Certain Agreements of the Initial Purchasers. Each Initial Purchaser hereby represents and
agrees that it has not and will not use, authorize use of, refer to, or participate in the planning for use of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i) the
Preliminary Offering Memorandum and the Offering Memorandum, (ii) a written communication that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through
incorporation by reference) in the Preliminary Offering Memorandum or the Offering Memorandum, (iii) any written communication listed on Annex A or prepared pursuant to Section 4(c) above (including any electronic road show), (iv) any
written communication prepared by such Initial Purchaser and approved by the Company in advance in writing or (v) any written communication relating to or that contains the terms of the Securities and/or other information that was included
(including through incorporation by reference) in the Preliminary Offering Memorandum or the Offering Memorandum. 
 6. Conditions of
Initial Purchasers’ Obligations. The obligation of each Initial Purchaser to purchase Securities on the Closing Date as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the
following additional conditions: 
 (a) Representations and Warranties. The representations and warranties of the Company contained
herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the
Closing Date. 
 (b) No Downgrade. Subsequent to the earlier of (A) the Time of Sale and (B) the execution and delivery of
this Agreement, (i) no downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries by any “nationally recognized
statistical rating organization”, as such term is defined by the Commission for purposes of Rule 436(g)(2) under the Securities Act; and (ii) no such organization shall have publicly announced that it has under surveillance or review, or
has changed its outlook with respect to, its rating of the Securities or of any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive implications of a
possible upgrading). 
 (c) No Material Adverse Change. No material change in the capital stock or long term debt of the Company and
no event or condition of a type described in Section 3(d) hereof shall have occurred or shall exist, which change, event or condition is not described in each of the Time of Sale Information (excluding any amendment or supplement thereto) and
the Offering Memorandum (excluding any amendment or supplement thereto) the effect of which in the judgment of the Initial Purchasers makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms
and in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum. 

 (d) Officer’s Certificate. The Initial Purchasers shall have received on and as of the
Closing Date a certificate of an executive officer of the Company who has specific knowledge of the Company’s financial matters and is satisfactory to the Initial Purchasers (i) confirming that such officer has carefully reviewed the Time
of Sale Information and the Offering Memorandum and, to the best knowledge of such officer, the representations set forth in Sections 3(a) and 3(b) hereof are true and correct, (ii) confirming that the other representations and warranties of
the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date and (iii) to the effect
set forth in paragraphs (b) and (c) above. 
 (e) Comfort Letters. On the date of this Agreement and on the Closing Date,
each of Ernst & Young LLP, PricewaterhouseCoopers AB and Grant Thornton LLP shall have furnished to the Initial Purchasers, at the request of the Company, OMX and PHLX, respectively, letters, dated the respective dates of delivery thereof
and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Initial Purchasers, containing statements and information of the type customarily included in accountants’ “comfort letters” to underwriters
with respect to the financial statements and certain financial information contained in each of the Time of Sale Information and the Offering Memorandum; provided that the letter delivered on the Closing Date shall use a “cut-off”
date no more than three business days prior to the Closing Date. 
 (f) Opinion and 10b-5 Statement of Counsel, Opinion of Foreign Counsel
and Opinion of Local Counsel for the Company. Skadden, Arps, Slate, Meagher & Flom LLP, counsel for the Company, shall have furnished to the Initial Purchasers, at the request of the Company, their written opinion and 10b-5 statement;
Edward S. Knight, Executive Vice-President and General Counsel of the Company, shall have furnished to the Initial Purchasers his written opinion; Magnus Billing, General Counsel of OMX AB, shall have furnished to the Initial Purchasers his written
opinion; and Advokatfirman Cederquist KB, foreign counsel for the Company, shall have furnished to the Initial Purchasers at the request of the Company, their written opinion, in each case dated the Closing Date and addressed to the Initial
Purchasers, in form and substance reasonably satisfactory to the Initial Purchasers, to the effect set forth in Annex C-1, C-2, C-3 and C-4 hereto, respectively. 
 (g) Opinion and 10b-5 Statement of Counsel and Opinion and 10b-5 Statement of Foreign Counsel for the Initial Purchasers. The Initial Purchasers shall have received on and as of the Closing Date an opinion of
Davis Polk & Wardwell and an opinion and 10b-5 statement of Cahill Gordon & Reindel LLP, each counsel for the Initial Purchasers, with respect to such matters as the Initial Purchasers may reasonably request, and
each such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. 
 (h) No Legal Impediment to Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that
would, as of the Closing Date, prevent the issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the
Securities. 

 (i) Good Standing. The Initial Purchasers shall have received on and as of the Closing Date
satisfactory evidence of the good standing of the Company in its jurisdiction of organization and its good standing in such other jurisdictions as the Initial Purchasers may reasonably request, in each case in writing or any standard form of
telecommunication, from the appropriate governmental authorities of such jurisdictions. 
 (j) Registration Rights Agreement. The
Initial Purchasers shall have received a counterpart of the Registration Rights Agreement that shall have been executed and delivered by a duly authorized officer of the Company. 
 (k) PORTAL and DTC. The Securities shall have been approved by FINRA for trading in the PORTAL Market and shall be eligible for clearance and
settlement through DTC. 
 (l) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit B
hereto, of the officers and directors of the Company identified on Exhibit B relating to sales and certain other dispositions of shares of Common Stock or certain other securities, shall have been delivered to the Initial Purchasers on or before the
date hereof and shall be in full force and effect on the Closing Date; 
 (m) Listing. An application for the listing of the
Underlying Securities shall have been submitted to the Exchange; 
 (n) Additional Documents. On or prior to the Closing Date, the
Company shall have furnished to the Initial Purchasers such further certificates and documents as the Initial Purchasers may reasonably request. 
 (o) Other Transactions. The Initial Purchasers shall be reasonably satisfied that the Equity Investment shall have been or will be received by the Company, the Credit Facilities shall have been or will be funded, and each of the
other Transactions shall have been or will be consummated prior to July 31, 2008. 
 All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Initial Purchasers. 
 7. Indemnification and Contribution. 
 (a) Indemnification of the Initial Purchasers. The Company agrees to indemnify and hold harmless each Initial Purchaser, its affiliates, directors and officers and each person, if any, who controls such Initial Purchaser within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with
any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary
Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication or the Offering Memorandum (or any amendment or supplement thereto) or any omission or alleged omission to state therein a material fact necessary in
order to make the statements therein, in the light of the 

 
circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are
based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser
expressly for use therein. 
 (b) Indemnification of the Company. Each Initial Purchaser agrees, severally and not jointly, to
indemnify and hold harmless the Company, each of its directors and officers and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as
the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with any information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser expressly for use in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any
Issuer Written Communication or the Offering Memorandum (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the following: the fifth and sixth sentence in the eleventh paragraph, and
the thirteenth paragraph, each in the section entitled “Plan of distribution.” 
 (c) Notice and Procedures. If any suit,
action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above,
such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person
shall not relieve it from any liability that it may have under this Section 7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided,
further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under this Section 7. If any such proceeding shall be brought or asserted
against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person,
be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section 7 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses
of such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel
reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying
Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to
actual or potential differing interests between them. It is understood and agreed that the Indemnifying 

 
Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be reimbursed as they are incurred. Any such separate firm for any Initial Purchaser, its affiliates, directors and officers and
any control persons of such Initial Purchaser shall be designated in writing by J.P. Morgan Securities Inc. and any such separate firm for the Company, its directors and officers and any control persons of the Company shall be designated in writing
by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees
to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person
reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is
entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No
Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have
been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability or claims
that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. 
 (d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable
by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Initial Purchasers on the other from
the offering of the Securities or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the
relative fault of the Company on the one hand and the Initial Purchasers on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Initial Purchasers on the other shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company
from the sale of the Securities and the total discounts and commissions received by the Initial Purchasers in connection therewith, as provided in this Agreement, bear to the aggregate offering price of the Securities. The relative fault of the
Company on the one hand and the Initial Purchasers on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

 (e) Limitation on Liability. The Company and the Initial Purchasers agree that it would not be
just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed
to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this Section 7, in no event shall an Initial
Purchaser be required to contribute any amount in excess of the amount by which the total discounts and commissions received by such Initial Purchaser with respect to the offering of the Securities exceeds the amount of any damages that such Initial
Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers’ obligations to contribute pursuant to this Section 7 are several in proportion to their respective purchase
obligations hereunder and not joint. 
 (f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive
and shall not limit any rights or remedies that may otherwise be available to any Indemnified Person at law or in equity. 
 8.
Termination. This Agreement may be terminated in the absolute discretion of the Initial Purchasers, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading generally
shall have been suspended or materially limited on The NASDAQ Stock Market or The New York Stock Exchange or the over-the-counter market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any
exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of
hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Initial Purchasers, is material and adverse and makes it impracticable or inadvisable to proceed with
the offering, sale or delivery, of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum. 
 9. Defaulting Initial Purchaser. 
 (a) If, on the Closing Date, any Initial Purchaser defaults on its
obligation to purchase the Securities that it has agreed to purchase hereunder, the non-defaulting Initial Purchasers may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms
contained in this Agreement. If, within 36 hours after any such default by any Initial Purchaser, the non-defaulting Initial Purchasers do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36
hours within which 

 
to procure other persons satisfactory to the non-defaulting Initial Purchasers to purchase such Securities on such terms. If other persons become obligated
or agree to purchase the Securities of a defaulting Initial Purchaser, either the non defaulting Initial Purchasers or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion of
counsel for the Company or counsel for the Initial Purchasers may be necessary in the Time of Sale Information, the Offering Memorandum or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement
to the Time of Sale Information or the Offering Memorandum that effects any such changes. As used in this Agreement, the term “Initial Purchaser” includes, for all purposes of this Agreement unless the context otherwise requires, any
person not listed in Schedule 1 hereto that, pursuant to this Section 9, purchases Securities that a defaulting Initial Purchaser agreed but failed to purchase. 
 (b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the Company as provided in
paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased does not exceed one-eleventh of the aggregate principal amount of all the Securities, then the Company shall have the right to require each
non-defaulting Initial Purchaser to purchase the principal amount of Securities that such Initial Purchaser agreed to purchase hereunder plus such Initial Purchaser’s pro rata share (based on the principal amount of Securities that such
Initial Purchaser agreed to purchase hereunder) of the Securities of such defaulting Initial Purchaser or Initial Purchasers for which such arrangements have not been made. 
 (c) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by the
non-defaulting Initial Purchasers and the Company as provided in paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased exceeds one-eleventh of the aggregate principal amount of all the Securities, or if
the Company shall not exercise the right described in paragraph (b) above, then this Agreement shall terminate without liability on the part of the non-defaulting Initial Purchasers. Any termination of this Agreement pursuant to this
Section 9 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section 10 hereof and except that the provisions of Section 7 hereof shall
not terminate and shall remain in effect. 
 (d) Nothing contained herein shall relieve a defaulting Initial Purchaser of any liability it
may have to the Company or any non-defaulting Initial Purchaser for damages caused by its default. 
 10. Payment of Expenses.

 (a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to
pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and
any taxes payable in that connection; (ii) the costs incident to the preparation and printing of the Preliminary Offering Memorandum, any other Time of Sale Information, any 

 
Issuer Written Communication and the Offering Memorandum (including any amendment or supplement thereto) and the distribution thereof; (iii) the costs
of reproducing and distributing each of the Transaction Documents; (iv) the fees and expenses of the Company’s counsel and independent accountants; (v) the fees and expenses incurred in connection with the registration or
qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Initial Purchasers may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the
related fees and expenses of counsel for the Initial Purchasers); (vi) any fees charged by rating agencies for rating the Securities; (vii) the fees and expenses of the Trustee and any paying agent (including related fees and expenses of
any counsel to such parties); (viii) all expenses and application fees incurred in connection with the application for the inclusion of the Securities on the PORTAL Market and the approval of the Securities for book-entry transfer by DTC;
(ix) any fees or costs incident to listing the Underlying Securities on the Exchange; and (x) all expenses incurred by the Company in connection with any “road show” presentation to potential investors; provided that the
Initial Purchasers will pay or cause to be paid one-half of the cost of any chartered aircraft used in connection with such “road show” presentations. 
 (b) If this Agreement is terminated pursuant to Section 8, the Company agrees to reimburse the Initial Purchasers for the reasonable fees and expenses of their counsel incurred in connection with this Agreement
and the offering contemplated hereby. 
 (c) If (i) the Company for any reason fails to tender the Securities for delivery to the
Initial Purchasers or (ii) the Initial Purchasers decline to purchase the Securities for any reason permitted under Section 6 of this Agreement, the Company agrees to reimburse the Initial Purchasers for all out-of-pocket costs and
expenses (including the reasonable fees and expenses of their counsel) reasonably incurred by the Initial Purchasers in connection with this Agreement and the offering contemplated hereby. 
 11. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their
respective successors and any controlling persons referred to herein, and the affiliates, officers and directors of each Initial Purchaser referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give any
other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor merely by reason of such
purchase. 
 12. Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the
Company and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company or the Initial Purchasers pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the
Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Initial Purchasers. 
 13. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate” has
the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; (c) the term “Exchange Act”
means the 

 
Securities Exchange Act of 1934, as amended; (d) the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act, and
with regards to the Company includes OMX, PHLX and their subsidiaries except where otherwise expressly provided; (e) the term “counsel for the Company” as used in Section 1(c) hereof means Skadden, Arps, Slate, Meagher &
Flom LLP; and (f) the term “written communication” has the meaning set forth in Rule 405 under the Securities Act. Any representation or warranty of the Company made under Section 3 with respect to OMX, PHLX and their
subsidiaries is limited in its entirety to the knowledge of the Company with respect to such matter. 
 14. Miscellaneous. 

(a) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or
transmitted and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Initial Purchasers c/o J.P. Morgan Securities Inc., 277 Park Avenue, New York, New York 10172 (fax: 212-622-8358);
Attention: syndicate desk. Notices to the Company shall be given to The Nasdaq Stock Market, One Liberty Plaza, 50th Floor, New York, New York 10006, (fax: 301-978-8472); Attention: Office of General Counsel; with a copy to Skadden, Arps, Slate,
Meagher & Flom LLP, 4 Times Square, New York, New York 10036 (fax: 212-735-2000); Attention: Phyllis Korff and Eric Friedman. 
 (b)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 
 (c)
Counterparts. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same
instrument. 
 (d) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to
any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. 
 (e)
Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. 

 If the foregoing is in accordance with your understanding, please indicate your acceptance of this
Agreement by signing in the space provided below. 
  

			
	Very truly yours,
	
	THE NASDAQ STOCK MARKET, INC.
		
	By:	 	 /s/ Ron Hassen

	Name:	 	Ronald Hassen
	Title:	 	Senior Vice President, Controller

 The foregoing Purchase Agreement is hereby confirmed and accepted the Initial Purchasers as of the date
first written above. 
  

							
	 J.P. MORGAN SECURITIES INC.
 BANC OF AMERICA SECURITIES LLC
as Initial Purchasers
	 	 
			
	By:	 	J.P. Morgan Securities Inc.	 	
			
	By:	 	 /s/ Santosh Sreenivansan
	 	
	Title:	 	Executive Director	 	
			
	By:	 	Banc of America Securities LLC	 	
			
	By:	 	 /s/ Derek Dillon
	 	
	Title:	 	Managing Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]